The company's Prader-Willi treatment inched closer to FDA approval. Soleno Therapeutics (SLNO 9.11%) had some good news to report on the regulatory front on Tuesday. Investors were cheered by this as evidenced by their sending the biotech's stock more than 9% higher in price on the day. This performance was much better than that of the closely watched S&P 500 index, which closed up by less than 1%. Skipping ahead in the review process? Before market open that day, Soleno reported that the U.S. Food and Drug ...